INVO Stock Price, INVO BioScience, Inc. Quote, Chart

Market Summary

USD0.980.00

Delayed

0.00%

INVO Stock Price

View Fullscreen

INVO RSI Chart

INVO Valuation

Market Cap

2.4M

Price/Earnings (Trailing)

-0.36

Price/Sales (Trailing)

0.81

EV/EBITDA

-0.34

Price/Free Cashflow

-0.47

INVO Price/Sales (Trailing)

INVO Profitability

Operating Margin

69.53%

EBT Margin

-272.16%

Return on Equity

-759.42%

Return on Assets

-32.46%

Free Cashflow Yield

-212.87%

INVO Fundamentals

INVO Revenue

Revenue (TTM)

3.0M

Rev. Growth (Yr)

314.28%

Rev. Growth (Qtr)

208.61%

INVO Earnings

Earnings (TTM)

-6.8M

Earnings Growth (Yr)

25.84%

Earnings Growth (Qtr)

-154.71%

Breaking Down INVO Revenue

Last 7 days

-28.5%

Last 30 days

-10.9%

Last 90 days

-5.8%

Trailing 12 Months

159.3%

How does INVO drawdown profile look like?

INVO Financial Health

Current Ratio

0.15

INVO Investor Care

Shares Dilution (1Y)

309.54%

Diluted EPS (TTM)

-6.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	975.5K	1.8M	3.0M
2022	3.6M	3.6M	3.6M	822.2K
2021	1.5M	1.4M	1.3M	4.2M
2020	1.5M	1.1M	1.2M	1.0M
2019	579.7K	1.1M	1.3M	1.5M
2018	334.0K	363.9K	420.7K	494.4K
2017	85.0K	159.9K	210.3K	282.1K
2016	26.2K	26.1K	41.4K	50.9K
2015	10.5K	13.9K	11.7K	11.7K
2014	28.5K	27.0K	31.5K	16.6K
2013	53.4K	44.3K	41.0K	27.1K
2012	49.7K	40.6K	31.4K	56.4K
2011	0	0	0	71.5K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of INVO BioScience, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 01, 2022	messina rebecca	bought	9,374	0.95	9,868	-
Jun 01, 2022	davis trent d	bought	10,624	0.95	11,184	-
Jun 01, 2022	segal jeffrey	bought	8,750	0.95	9,211	-
Jun 01, 2022	goren andrea	bought	50,000	0.95	52,632	chief financial officer
Jun 01, 2022	ryan barbara	bought	9,999	0.95	10,526	-
Jun 01, 2022	szot matthew k	bought	13,750	0.95	14,474	-
Jun 01, 2022	doody kevin	bought	-168,441	0.95	-177,306	medical director
Jun 01, 2022	campbell michael jos.	bought	9,999	0.95	10,526	chief operating officer
Jun 01, 2022	shum steve	bought	55,940	0.95	58,885	chief executive officer
Jan 15, 2022	davis trent d	acquired	-	-	8,865	-

Which funds bought or sold INVO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Aspire Private Capital, LLC	unchanged	-	-25.00	130	-%
Apr 12, 2024	Gleason Group, Inc.	unchanged	-	-1.00	3.00	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	72,978	72,978	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	reduced	-91.94	-157,412,000	25,142,000	0.03%
Feb 14, 2024	AWM Investment Company, Inc.	sold off	-100	-25,286	-	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	1,000	1,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-28,600	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	84.31	4,556	6,676	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-9.76	18.00	50.00	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	13.00	32.00	-%

Are Funds Buying or Selling INVO?

Are funds buying INVO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INVO

No. of Funds

Unveiling INVO BioScience, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	intracoastal capital, llc	6.9%	184,000	SC 13G/A
Sep 08, 2023	awm investment company, inc.	2.6%	63,193	SC 13G/A
Aug 11, 2023	intracoastal capital, llc	7.1%	184,000	SC 13G
Feb 14, 2023	awm investment company, inc.	5.1%	623,860	SC 13G/A
Feb 23, 2022	ranoux claude	6.53%	766,189	SC 13G
Feb 11, 2022	awm investment company, inc.	9.9%	1,159,075	SC 13G/A
May 11, 2021	awm investment company, inc.	11.1%	1,154,153	SC 13G/A
Feb 12, 2021	awm investment company, inc.	6.5%	625,000	SC 13G

Recent SEC filings of INVO BioScience, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	8-K	Current Report
Apr 17, 2024	8-K	Current Report
Apr 17, 2024	10-K/A	Annual Report
Apr 16, 2024	8-K	Current Report
Apr 16, 2024	10-K	Annual Report
Apr 11, 2024	8-K	Current Report
Apr 02, 2024	8-K/A	Current Report
Apr 01, 2024	NT 10-K	NT 10-K
Apr 01, 2024	8-K	Current Report
Mar 29, 2024	424B5	Prospectus Filed

Peers (Alternatives to INVO BioScience, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

INVO BioScience, Inc. News

Latest updates

INVO BioScience, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-100.0%	-	974,894	315,902	278,142	235,321	146,135	162,598	3,048,247	218,874	208,472	684,523	196,572	336,071	246,072	258,571	328,572	303,571	658,638	189,432	154,990	125,035
Cost Of Revenue	-	-	-	886,620	-147,863	109,116	532,366	64,961	47,294	20,418	14,595	62,745	10,198	27,398	21,170	29,994	28,484	44,926	55,282	10,978	43,864	15,369
Gross Profit	-	-	-	463,383	-49,660	126,205	565,099	97,637	3,000,953	198,456	193,877	621,778	186,374	308,673	224,902	228,577	300,088	258,645	603,356	178,454	111,126	109,666
Operating Expenses	114.1%	3,985,216	1,861,184	264,446	3,948,892	2,760,739	324,980	2,798,575	2,497,398	2,472,182	2,080,438	2,181,570	1,974,128	1,576,439	1,287,829	1,625,096	1,040,910	891,008	669,152	527,565	624,575	299,548
S&GA Expenses	40.6%	1,767,199	1,257,044	2,042,609	3,191,000	2,316,763	2,444,586	2,694,395	2,433,642	2,416,791	2,049,422	2,115,303	1,753,194	1,463,887	1,252,939	1,595,046	1,040,910	891,008	669,152	527,565	624,575	299,548
R&D Expenses	121.4%	5,907	2,668	83,850	73,835	175,267	190,761	104,180	63,756	55,391	31,016	66,267	220,934	112,552	34,890	30,050	-	-	-	-	-	-
EBITDA Margin	47.0%	-2.38	-4.49	-10.25	-9.58	-2.08	-1.86	-1.72	-1.29	-5.69	-4.44	-3.87	-5.30	-3.80	-	-	-	-	-	-	-	-
Interest Expenses	-23.4%	269,616	352,085	47.00	56,133	1,761	88.00	1,456	186,464	92,544	91,125	895,226	2,024,616	504,061	259,954	47,873	54,969	47,462	175,756	109,459	257,931	104,978
Income Taxes	1121.4%	23,035	1,886	2,865	2,072	-	800	-	3,852	456	-	912	-495	-	-	-	-30,076	30,509	-	-	-	-
Earnings Before Taxes	-58.2%	-1,971,747	-1,246,554	-2,237,646	-2,764,963	-2,549,623	-2,800,741	-	101,782	-2,481,326	-1,817,163	-2,453,469	-3,808,180	-1,771,827	-1,322,881	-1,444,392	-787,164	-679,825	-241,552	-458,570	-771,380	-294,860
EBT Margin	44.2%	-2.72	-4.88	-10.61	-9.75	-2.15	-1.96	-1.83	-1.60	-8.07	-6.91	-6.39	-8.05	-4.56	-	-	-	-	-	-	-	-
Net Income	-154.7%	-3,179,870	-1,248,440	198,890	-4,287,880	-2,549,623	240,150	-2,774,312	-141,525	-2,242,783	-1,817,163	-2,453,469	-3,808,216	-1,771,827	-1,322,881	-1,444,392	-757,088	-710,334	-241,552	-458,570	-771,380	-294,860
Net Income Margin	48.7%	-2.24	-4.37	-9.42	-11.40	-1.45	-1.38	-1.92	-1.60	-7.89	-6.91	-6.39	-8.05	-4.53	-	-	-	-	-	-	-	-
Free Cashflow	83.3%	-789,883	-4,725,209	1,725,417	-1,004,010	-6,376,168	2,849,847	-2,083,773	-1,182,569	-1,638,404	-1,202,486	-1,764,117	-1,849,058	-940,409	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	7.2%	20,888	19,476	1,623	6,151	4,104	4,678	6,425	8,520	10,466	8,146	9,931	10,190	10,947	1,689	2,306	958	1,795	2,565	3,396	3,503	777
Current Assets	-29.7%	1,260	1,792	700	2,810	621	942	2,548	4,421	6,306	5,330	7,232	9,583	10,543	1,372	2,041	689	1,543	2,304	3,175	3,411	731
Cash Equivalents	-100.0%	-	1,056	459	2,188	90.00	286	1,962	3,840	5,685	4,713	6,643	8,423	10,098	908	1,504	350	1,239	2,010	2,663	3,057	212
Inventory	4.0%	265	254	280	271	264	280	282	295	288	290	251	268	265	241	244	162	101	69.00	76.00	52.00	44.00
Net PPE	7.0%	826	772	67.00	418	437	456	473	492	501	854	127	130	132	106	109	111	93.00	96.00	98.00	82.00	34.00
Goodwill	-28.5%	5,879	8,225	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	4.7%	19,995	19,103	1,781	6,063	5,081	3,391	3,068	2,930	3,156	5,789	5,573	4,592	5,204	5,591	5,904	5,393	5,509	6,325	6,555	6,606	3,502
Current Liabilities	68.3%	8,219	4,884	1,112	4,450	3,409	1,661	1,280	1,084	1,253	2,140	1,717	1,860	2,288	1,883	1,621	1,924	1,501	2,185	2,279	6,606	3,502
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	341	250	185	536	-	-	-	-	-	-	-	-
Shareholder's Equity	139.5%	893	373	-	88.00	-977	1,287	3,356	5,590	7,311	2,356	4,358	5,598	5,743	-	-	-	-	-	-	-	-
Retained Earnings	-3.6%	-57,818	-55,800	-54,574	-52,334	-49,800	-47,016	-44,466	-41,665	-38,891	-38,749	-36,506	-34,689	-32,236	-28,427	-26,656	-25,333	-23,888	-23,131	-22,421	-22,179	-21,721
Additional Paid-In Capital	-6.2%	52,711	56,196	52,869	52,423	48,806	48,303	47,822	47,254	46,201	41,343	40,864	40,287	37,978	24,525	23,057	20,897	20,175	19,356	19,247	19,062	18,997
Accumulated Depreciation	-	234	-	-	-	153	-	-	-	-	-	-	-	-	50.00	-	-	42.00	-	-	-	-
Shares Outstanding	0.7%	2,493	2,475	827	699	609	608	604	603	-	513	508	494	482	-	-	-	-	-	-	-	-
Float	-	-	-	3,072	-	-	-	7,763	-	-	-	46,939	-	-	-	19,556	-	21,787	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	84.5%	-714	-4,616	1,725	-1,148	-1,004	-6,373	2,853	-2,078	-1,511	-1,609	-1,173	-1,735	-1,820	-940	-1,150	-863	-771	-568	-377	3,088	-286
Share Based Compensation	-100.0%	-	252	327	326	329	426	433	428	392	391	384	377	463	67.00	55.00	381	70.00	-	-	-	-
Cashflow From Investing	101.5%	33.00	-2,258	-261	-8.45	9.00	-3.01	-4.90	-81.89	-917	-320	-606	-308	-96.57	-60.95	-4.59	-25.13	-	-49.87	-16.44	-48.40	-19.40
Cashflow From Financing	-101.7%	-141	8,439	-4,159	3,255	800	1,369	-1,394	315	3,401	-	-	370	11,106	406	2,310	-	-	-35.00	-	-194	-30.00

INVO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 3,020,575	$ 822,196
Operating expenses:
Cost of revenue	1,934,437	850,770
Selling, general and administrative expenses	7,486,454	9,976,563
Research and development expenses	165,945	544,043
Depreciation and amortization	200,894	77,301
Total operating expenses	9,787,730	11,448,677
Loss from operations	(6,767,155)	(10,626,481)
Other income (expense):
Loss from equity method joint ventures	(60,270)	(200,558)
Impairment from equity method joint venture	(89,794)
Loss from debt extinguishment	(163,278)
Interest income		308
Interest expense	(925,909)	(59,445)
Foreign currency exchange loss	(420)	(3,463)
Total other expenses	(1,239,671)	(263,158)
Net loss before income taxes	(8,006,826)	(10,889,639)
Provision for income taxes	27,786	2,872
Net loss	$ (8,034,612)	$ (10,892,511)
Net loss per common share:
Basic	$ (5.13)	$ (17.97)
Diluted	$ (5.13)	$ (17.97)
Weighted average number of common shares outstanding:
Basic	1,565,951	606,130
Diluted	1,565,951	606,130
Clinic Revenue [Member]
Revenue:
Total revenue	$ 2,862,574	$ 614,854
Product [Member]
Revenue:
Total revenue	$ 158,001	$ 207,342

INVO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 232,424	$ 90,135
Accounts receivable	140,550	77,149
Inventory	264,507	263,602
Prepaid expenses and other current assets	622,294	190,201
Total current assets	1,259,775	621,087
Property and equipment, net	826,418	436,729
Lease right of use	5,740,929	1,808,034
Intangible assets, net	4,093,431
Goodwill	5,878,986
Investment in NAYA	2,172,000
Equity investments	916,248	1,237,865
Total assets	20,887,787	4,103,715
Current liabilities
Accounts payable and accrued liabilities	2,330,381	1,349,038
Accrued compensation	722,251	946,262
Deferred revenue	408,769	119,876
Lease liability, current portion	397,554	231,604
Additional payments for acquisition, current portion	2,500,000
Other current liabilities	350,000
Total current liabilities	8,218,875	3,409,424
Lease liability, net of current portion	5,522,090	1,669,954
Notes payable – net of current portion	1,253,997
Deferred tax liability		1,949
Additional payments for acquisition, net of current portion	5,000,000
Total liabilities	19,994,962	5,081,327
Stockholders’ equity (deficit)
Common Stock, $.0001 par value; 50,000,000 shares authorized; 2,492,531 and 608,611 issued and outstanding as of December 31, 2023 and 2022, respectively	249	61
Additional paid-in capital	52,710,721	48,805,860
Accumulated deficit	(57,818,145)	(49,783,533)
Total stockholders’ equity (deficit)	892,825	(977,612)
Total liabilities and stockholders’ equity (deficit)	20,887,787	4,103,715
Series B Preferred Stock [Member]
Stockholders’ equity (deficit)
Series B Preferred Stock, $5.00 par value; 1,200,000 shares authorized; 1,200,000 and 0 issued and outstanding as of December 31, 2023 and 2022, respectively.	6,000,000
Nonrelated Party [Member]
Current liabilities
Notes payable, net	629,920	100,000
Related Party [Member]
Current liabilities
Notes payable, net	$ 880,000	$ 662,644

About INVO BioScience, Inc.

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.

CEO	Mr. Steven M. Shum
WEBSITE	invobio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	15

INVO BioScience, Inc. Frequently Asked Questions

What is the ticker symbol for INVO BioScience, Inc.? What does INVO stand for in stocks?

INVO is the stock ticker symbol of INVO BioScience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of INVO BioScience, Inc. (INVO)?

As of Fri Apr 26 2024, market cap of INVO BioScience, Inc. is 2.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INVO stock?

You can check INVO's fair value in chart for subscribers.

What is the fair value of INVO stock?

You can check INVO's fair value in chart for subscribers. The fair value of INVO BioScience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of INVO BioScience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INVO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is INVO BioScience, Inc. a good stock to buy?

The fair value guage provides a quick view whether INVO is over valued or under valued. Whether INVO BioScience, Inc. is cheap or expensive depends on the assumptions which impact INVO BioScience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INVO.

What is INVO BioScience, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, INVO's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 0.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INVO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on INVO BioScience, Inc.'s stock?

In the past 10 years, INVO BioScience, Inc. has provided 0.356 (multiply by 100 for percentage) rate of return.